Pfizer (PFE): Reassessing Valuation After Cautious 2026 Outlook and Fading COVID-19 Revenue

Pfizer (PFE) just laid out a 2026 outlook that underwhelmed the market, with lower expected earnings and revenue as COVID-19 ...

Pfizer: Downgrade To 'Hold' On Lower 2026 Revenue Guidance And Potential Growth Tracks

Pfizer is pursuing pipeline expansions through the Metsera acquisition and a major licensing deal with 3SBio. Find out why ...
Reuters

Deaths in Pfizer arthritis trial under microscope

LONDON (Reuters) - Four deaths during a study of Pfizer's new rheumatoid arthritis pill will be pored over at a medical meeting in London this week, as doctors weigh the drug's chances of upending ...
The Globe and Mail

Pfizer and Genmab’s Tivdak Study: Ocular Side Effects Under the Microscope

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Pfizer Inc. and Genmab are conducting a ...